Welcome : Guest

PHARMACEUTICAL CONTRACT MANUFACTURING - A GLOBAL STRATEGIC BUSINESS REPORT   

Research Abstract

This report analyzes the worldwide markets for Pharmaceutical Contract Manufacturing in US$ Thousand by the following Dosage Forms: Injectables, Solid Dosage Forms, and Liquid & Semi-solid Dosage Forms. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 112 companies including many key and niche players such as -

Aenova Group
Ajinomoto Althea, Inc.
Albany Molecular Research Inc.
Alcami Corporation
Baxter International, Inc.

Click here to request a full list of companies covered in the report...

Code: MCP-1535
Price: $4950
Companies: 112
Pages: 347
Date: January 2017
Market Data Tables: 60
  Status: * New Report



TABLE OF CONTENTS


  PHARMACEUTICAL CONTRACT MANUFACTURING (Complete Report) Pages : 347   | $4950

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Product Definitions and Scope of Study.....I-3  
   Pharmaceutical Contract Manufacturing – A Prelude.....II-1
Current & Future Market Outlook.....II-1
1$100
   Sizing the Market.....II-21$100
   West Leads in PCM Services.....II-3
Solid Dosage Remains Popular Among CMOs.....II-3
1$100
   Injectable-Dose Formulations to Spearhead Growth of the PCM Market.....II-41$100
   Opportunities Rife for PCM Growth.....II-5
Key Market Drivers.....II-5
Major Changes Imperative to Capitalize on Brighter Future Prospects.....II-5
2$200
   Changing Face of the CMO Industry.....II-7
Relevance of CMOs Increases in the Modern Pharma Industry.....II-7
Patent Expiries Augur Good Tidings for the PCM Market.....II-7
1$100
   PCMs Gear Up to Tap Booming Biologics Market.....II-8
Biotechnology Start-Ups Spur Demand for Contract Manufacturing.....II-8
Service Differentiation – The Key to Future Success in Solid Dosage Formulations
  Manufacturing.....II-8
1$100
   Strong Growth in Injectables Market to Resonate in Contract Manufacturing.....II-9
Developed Markets Dominate Sterile Injectables Contract Manufacturing Market.....II-9
PCM Market for Vaccines Yet to Take Off.....II-9
1$100
   PCM Industry Gravitates Eastward, and Subsequently Leads to Near-Shoring.....II-10
Smaller Production Batches are Here to Stay; Compel Facility Efficiency
  Improvements.....II-10
1$100
   Upstream Movement Becomes a Compulsion for Many.....II-111$100
   Need to Focus on Better Customer Services Emerges.....II-12
Rising Drug Complexity Presses for Specialized Expertise.....II-12
Adoption of Cutting-Edge Technologies to Radicalize PCM Environment.....II-12
1$100
   RABS technology.....II-13
Quality by Design.....II-13
Track & Trace Techniques.....II-13
1$100
   Disposable Processing Techniques.....II-14
Upstream & Downstream Processes.....II-14
Process Analytical Technology.....II-14
Near Infrared Spectroscopy.....II-14
Perfusion Technology Takes Center-stage as Quality and Cost Concerns Rise.....II-14
1$100
   Downstream Processes Get a Lift as CMOs Seek Ways to Improve Capacity.....II-15
Biopharma Contract Manufacturing Surges Ahead.....II-15
1$100
   Cost and Risk Containment Objectives Spur Outsourcing of Biopharma Production.....II-161$100
   Contract Manufacturing of ADCs Continues to Rise.....II-17
Competition to Surge in Biological Contract Manufacturing Market.....II-17
1$100
   CMOs Gear Up for Capacity Expansions to Address Growing Demand from Biopharma.....II-181$100
   Ballooning Global Population Offers Increased Growth Opportunities.....II-19 1$100
   Table 1: Top 25 Countries Worldwide in Terms of Population: 2015 & 2016 (includes corresponding Graph/Chart).....II-20
Aging Population Boosts Opportunities for PCM.....II-20
2$350
   Table 2: Global Population Statistics for the 65+ Age Group (2015) (includes corresponding Graph/Chart).....II-221$350
   Table 3: Comparison of Aging Population by Country (1980, 2015 & 2050): Percentage Share of Population Aged Above-65 Years of the Overall Population for Select Countries (includes corresponding Graph/Chart).....II-231$350
   Table 4: Life Expectancy for Select Countries in Number of Years: 2015E (includes corresponding Graph/Chart).....II-241$350
   Increasing Healthcare Expenditure to Spur Demand for Contract Manufacturing of
  Generics.....II-25
1$100
   Table 5: Healthcare Spending as a Percentage of GDP by Region (2016E) (includes corresponding Graph/Chart).....II-26

Table 6: Per-Capita Healthcare Expenditure in US$ for Select Countries/Regions (2014) (includes corresponding Graph/Chart).....II-26
1$350
   Surge in Generic Drugs to Benefit Pharmaceutical Contract Manufacturers.....II-27
Table 7: Worldwide Annual Spending on Drugs by Category (2011 & 2015): Percentage Breakdown of Dollar Sales for Branded Drugs, Generic Drugs, and Others (includes corresponding Graph/Chart).....II-27
1$350
   Insourcing of Manufacturing Operations – An Emerging Threat to PCM.....II-281$100
   Vendor Switching- A Growing Concern for PCMs.....II-291$100
   New Challenges Threaten Prospects for CMOs.....II-301$100
   New Distribution Regulations Incites Changes in Operations.....II-311$100
   PCM – A Highly Fragmented Industry Undergoing Consolidation.....II-32
Table 8: Leading Players in the Global Finished Dose Pharmaceutical Contract Manufacturing Market (2015): Percentage Breakdown of Revenues for Aenova, Baxter, Catalent, Famar, Fareva, LTS Lohmann, Nipro, Patheon/DPx, Pfizer/Hospira, Vetter and Others (includes corresponding Graph/Chart).....II-32
1$350
   Table 9: Worldwide Injectables Contract Manufacturing Market by Leading Players (2013): Percentage Breakdown of Value Sales for Baxter, Hospira, Vetter and Others (includes corresponding Graph/Chart).....II-33
PCMs Battle Fierce Competition and Commoditization.....II-33
Consolidation Wave Hits the Market.....II-33
1$350
   Select Key CMO Mergers and Acquisitions: 2014-2016.....II-342$200
   Changing Focus on M&A Activity.....II-36
Investments Rise as CMOs Respond to Changing Market Needs.....II-36
2$200
   Capacity Expansions Become Popular Options for Building Integrated Service
  Offerings.....II-38
Competition Heats Up in Injectables Market, PCMs Expand Capabilities and Service
  Offerings.....II-38
1$100
   Increased Regulator Scrutiny: A Cause of Concern for the Emerging Market PCMs.....II-391$100
   Introduction.....II-40
Injectables (Injections, Vials, and IV solutions).....II-40
Solid Dosage Forms (SDFs) (Tablets and Capsules).....II-40
1$100
   Liquid Dosage Forms (LDFs) (Syrups and Suspensions).....II-41
An Insight into the Rise of Pharmaceutical Contract Manufacturing.....II-41
1$100
   Investment Risks in Pharmaceutical Contract Manufacturing.....II-42
Quality Assurance Risk.....II-42
Drug Development Risk.....II-42
Acquisition Risk.....II-42
Client Dependency Risk.....II-42
1$100
   KDPharma to Merge with Marine Ingredients.....II-43
Suanfarma Acquires Stake in Idifarma.....II-43
Recipharm Inks Long-Term Commercial Manufacturing Contract with Tillots.....II-43
Propanc Inks Contract Manufacturing Deal with AmatsiQBiologicals.....II-43
BioTechnique Commences Vaccine Manufacturing under Partnership with NPO.....II-43
Piramal Pharma Solutions Acquires Ash Stevens.....II-43
1$100
   Saneca Sells Registration Dossiers for 20 Products to Xantis, Retains Manufacturing
  Rights.....II-44
Evonik Takes Over Transferra.....II-44
Famar to Acquire Roche’s Leganes Site.....II-44
Mylan Acquires Part Business of Renaissance.....II-44
Averica and Dalton Pharma Ink Preferred Provider Agreement.....II-44
AGC Asahi Glass Takes Over Biomeva.....II-44
1$100
   BioDuro and Formex Merge.....II-45
Frontida Acquires Sun Pharma’s US Manufacturing Facilities.....II-45
Recipharm Inks Agreement to Take Over CDMO from Kemwell.....II-45
Generic Specialties Takes Over Axcellerate Pharma.....II-45
Pfizer Establishes Pfizer CentreOne Specialty CMO.....II-45
Caisson Biotech Inks Manufacturing Agreement with CordenPharma.....II-45
Brammer and Florida Biologix Merge.....II-45
1$100
   AAIPharma and Cambridge Major Laboratories Merge to form Alcami.....II-46
Recipharm to Acquire Mitim.....II-46
TxCell Signs CMO Deal with MaSTherCell.....II-46
Boehringer Ingelheim to Commence First Biopharma CMO Pilot Project in China.....II-46
Enteris Commences Contract Manufacturing Service at its Facility.....II-46
Capsugel Takes Over Powdersize and Xcelience.....II-46
Synerlab Acquires Alcala Farma.....II-46
1$100
   Recipharm Inks Deal to Take Over Majority Stake in Nitin Lifesciences.....II-47
Pfizer Acquires Hospira.....II-47
Avista Pharma Takes Over Scynexis CMO and Animal Health Businesses.....II-47
Lonza and Nikon Team Up for New Contract Manufacturing Facility.....II-47
Piramal Acquires Coldstream.....II-47
SK Capital Takes Over Halo Pharmaceutical.....II-47
FUJIFILM Acquires Kalon Biotherapeutics.....II-47
1$100
   Bayer Selects Cardinal Health as Contract Manufacturer for Xofigo®.....II-48
Recipharm Takes Over Manufacturing Facility and Contracts from Flamel.....II-48
Baring to Acquire Bushu Pharmaceuticals.....II-48
Recipharm Takes Over Lusomedicameta.....II-48
Strides Arcolab and Shasun to Merge.....II-48
Kinex Pharmaceuticals Acquires QuaDPharma.....II-48
Patheon Acquires Gallus BioPharmaceuticals.....II-48
Packaging Coordinators Takes Over Penn Pharma.....II-48
1$100
   Sun Pharmaceutical Takes Over Pharmalucence.....II-49
AMRI Acquires Oso Biopharmaceuticals Manufacturing.....II-49
Carlyle Group Takes Over Sunsho Pharmaceutical.....II-49
AMRI Acquires Cedarburg.....II-49
Par Pharmaceutical to Take Over JHP.....II-49
JLL Partners and Royal DSM Merger Businesses to form DPx.....II-49
Meiji Holdings Buys Medreich Lifecare Limited.....II-49
Emilia Group Takes Over Pharma Pac LLC.....II-49
Emergent BioSolutions Takes Over Cangene Corporation.....II-49
1$100
   Aenova Group (Germany).....II-50
Ajinomoto Althea, Inc. (US).....II-50
Albany Molecular Research Inc. (US).....II-50
1$100
   Alcami Corporation (US).....II-51
Baxter International, Inc. (US).....II-51
1$100
   Boehringer Ingelheim GmbH (Germany).....II-52
Catalent Pharma Solutions, Inc. (US).....II-52
1$100
   Cobra Biologics Holding AB (Sweden).....II-53
CordenPharma International (Germany).....II-53
1$100
   Dishman Group (India).....II-54
DPx Holdings B.V. (US).....II-54
1$100
   Fareva Group (Luxembourg).....II-55
Famar Health Care Services (Greece).....II-55
Hospira, Inc. (US).....II-55
1$100
   Jubilant Life Sciences Limited (India).....II-56
Kemwell Biopharma Pvt. Ltd. (India).....II-56
1$100
   Lonza Group Ltd. (Switzerland).....II-57
LTS Lohmann Therapie-Systeme AG (Germany).....II-57
1$100
   NextPharma Technologies Holding Ltd. (UK).....II-58
Nipro Pharma Corporation (Japan).....II-58
Recipharm AB (Sweden).....II-58
1$100
   Vetter Pharma International GmbH (Germany).....II-591$100
   Table 10: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).....II-601$350
   Table 11: World Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).....II-611$350
   Table 12: World 14-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....II-621$350
   Table 13: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).....II-631$350
   Table 14: World Historic Review for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).....II-641$350
   Table 15: World 14-Year Perspective for Pharmaceutical Contract Manufacturing of Injectables (Injections, Vials & Intravenous Solutions) by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....II-651$350
   Table 16: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).....II-661$350
   Table 17: World Historic Review for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).....II-671$350
   Table 18: World 14-Year Perspective for Pharmaceutical Contract Manufacturing of Solid Dosage Forms (Tablets & Capsules) by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....II-681$350
   Table 19: World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).....II-691$350
   Table 20: World Historic Review for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).....II-701$350
   Table 21: World 14-Year Perspective for Pharmaceutical Contract Manufacturing of Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) by Geographic Region - Percentage Breakdown of Annual Revenues for US, Canada, Japan, Europe, Asia-Pacific and Rest of World Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....II-711$350
   A. Market Analysis.....III-1
US PCM Market Overview.....III-1
1$75
   Domestic Contract Manufacturing Market Sees New Vigor.....III-2
Competitive Landscape.....III-2
1$75
   Strategic Corporate Developments.....III-34$300
   Select Key Players.....III-74$300
   B. Market Analytics.....III-11
Table 22: The US Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).....III-11
1$200
   Table 23: The US Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).....III-121$200
   Table 24: The US 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-131$200
   A. Market Analysis.....III-14
Current & Future Analysis.....III-14
Strategic Corporate Developments.....III-14
1$75
   B. Market Analytics.....III-15
Table 25: Canadian Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).....III-15
1$200
   Table 26: Canadian Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).....III-161$200
   Table 27: Canadian 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-171$200
   A. Market Analysis.....III-18
Current & Future Analysis.....III-18
Strategic Corporate Developments.....III-18
1$75
   Nipro Pharma Corporation – A Key Japanese Player.....III-191$75
   B. Market Analytics.....III-20
Table 28: Japanese Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).....III-20
1$200
   Table 29: Japanese Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).....III-211$200
   Table 30: Japanese 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-221$200
   A. Market Analysis.....III-23
Market Overview.....III-23
Injectables Segment Offers Promising Potential.....III-23
Mammalian Cell Technology Dominates PCM Market.....III-23
1$75
   Competitive Scenario.....III-24
Overview of Select Markets.....III-24
Germany.....III-24
Russia.....III-24
1$75
   B. Market Analytics.....III-25
Table 31: European Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain and Rest of European Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).....III-25
1$200
   Table 32: European Historic Review for Pharmaceutical Contract Manufacturing by Geographic Region - France, Germany, Italy, UK, Spain and Rest of European Markets Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).....III-261$200
   Table 33: European 14-Year Perspective for Pharmaceutical Contract Manufacturing by Geographic Region - Percentage Breakdown of Annual Revenues for France, Germany, Italy, UK, Spain and Rest of European Markets for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-271$200
   Table 34: European Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).....III-281$200
   Table 35: European Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).....III-291$200
   Table 36: European 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-301$200
   A. Market Analysis.....III-31
Current & Future Analysis.....III-31
Strategic Corporate Development.....III-31
1$75
   B. Market Analytics.....III-32
Table 37: French Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).....III-32
1$200
   Table 38: French Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).....III-331$200
   Table 39: French 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-341$200
   A. Market Analysis.....III-35
Current & Future Analysis.....III-35
Strategic Corporate Developments.....III-35
Key Players.....III-35
3$225
   B. Market Analytics.....III-38
Table 40: German Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).....III-38
1$200
   Table 41: German Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).....III-391$200
   Table 42: German 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-401$200
   A. Market Analysis.....III-41
Current & Future Analysis.....III-41
Strategic Corporate Development.....III-41
1$75
   B. Market Analytics.....III-42
Table 43: Italian Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).....III-42
1$200
   Table 44: Italian Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).....III-431$200
   Table 45: Italian 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-441$200
   A. Market Analysis.....III-45
Current & Future Analysis.....III-45
Strategic Corporate Development.....III-45
Key Player.....III-45
1$75
   B. Market Analytics.....III-46
Table 46: UK Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).....III-46
1$200
   Table 47: UK Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).....III-471$200
   Table 48: UK 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-481$200
   A. Market Analysis.....III-49
Current & Future Analysis.....III-49
Strategic Corporate Developments.....III-49
1$75
   B. Market Analytics.....III-50
Table 49: Spanish Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).....III-50
1$200
   Table 50: Spanish Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).....III-511$200
   Table 51: Spanish 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-521$200
   A. Market Analysis.....III-53
Current & Future Analysis.....III-53
Strategic Corporate Developments.....III-53
1$75
   Key Players.....III-542$150
   B. Market Analytics.....III-56
Table 52: Rest of European Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).....III-56
1$200
   Table 53: Rest of European Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).....III-571$200
   Table 54: Rest of European 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-581$200
   A. Market Analysis.....III-59
Favorable Government Policies Transform China and India into PCM Hubs.....III-59
Competitive Scenario.....III-59
1$75
   Overview of Select Key Markets.....III-60
India.....III-60
India – A Stronghold for Pharmaceutical Contract Manufacturing.....III-60
1$75
   Market Sees Transitory Turbulence.....III-61
Indian PCMs Battle Soaring Costs.....III-61
Outlook Remains Promising.....III-61
1$75
   China.....III-62
China Presents Enormous Opportunities for Contract Manufacturing.....III-62
1$75
   Strategic Corporate Developments.....III-63
Select Key Players.....III-63
3$225
   B. Market Analytics.....III-66
Table 55: Asia-Pacific Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).....III-66
1$200
   Table 56: Asia-Pacific Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).....III-671$200
   Table 57: Asia-Pacific 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-681$200
   Market Analysis.....III-69
Table 58: Rest of World Recent Past, Current and Future Analysis for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2015 through 2022 (includes corresponding Graph/Chart).....III-69
1$200
   Table 59: Rest of World Historic Review for Pharmaceutical Contract Manufacturing by Dosage Form - Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) Independently Analyzed with Annual Revenue Figures in US$ Thousand for the Years 2009 through 2014 (includes corresponding Graph/Chart).....III-701$200
   Table 60: Rest of World 14-Year Perspective for Pharmaceutical Contract Manufacturing by Dosage Form - Percentage Breakdown of Annual Revenues for Injectables (Injections, Vials & Intravenous Solutions), Solid Dosage Forms (Tablets & Capsules) and Liquid & Semi-solid Dosage Forms (Syrups, Suspensions, Gels, Creams & Ointments) for the Years 2009, 2016 and 2022 (includes corresponding Graph/Chart).....III-711$200
  
Total Companies Profiled: 112 (including Divisions/Subsidiaries - 125)

Region/Country Players

The United States 54 Canada 2 Japan 7 Europe 40 France 6 Germany 10 The United Kingdom 7 Italy 3 Spain 2 Rest of Europe 12 Asia-Pacific (Excluding Japan) 21 Middle East 1
Click here to request a full table of contents and more details on this project.